CXCR2 and metabolic dysfunction-associated steatohepatitis: Patients who progress from NASH to HCC are often associated with poor immunotherapy outcomes, and studies have shown that CXCR2 small-molecule inhibitors have the ability to reverse immunotherapy insensitivity in patients [28].